Although the combination of statin and fenofibrate is one of the options for patients with combined hyperlipidemia, non-lipid effects of it has not been completely understood yet. In this study we compared the effects of rosuvastatin 10 mg/fenofibrate 160 mg combination and rosuvastatin 10 mg monotherapy on muscle and liver enzyme, homocysteine levels, kidney, blood glucose control, and blood cell counts.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
180
rosuvastatin 10 mg/fenofibrate 160 mg per day
rosuvastatin 10 mg per day
Severance Hospital
Seoul, Seoul, South Korea
Incidence of elevation of CK>5x ULN or AST>3x ULN or ALT>3x ULN
Time frame: 24 weeks after drug treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.